PBTZ 169

Drug Profile

PBTZ 169

Alternative Names: PBTZ169

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
  • Developer NEARMEDIC
  • Class Antituberculars
  • Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 07 Nov 2017 Nearmedic suspends enrolment in a phase IIa trial in Tuberculosis (NCT03334734)
  • 16 Dec 2016 Phase-II clinical trials in Tuberculosis in Russia (PO) (NCT03334734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top